GENZYME LICENSES EXCLUSIVE RIGHTS TO CHRONIC MYELOID LEUKEMIA MARKERS

Genzyme Corporation (Nasdaq: GENZ -- News) announced today that it has entered into a license agreement with the University of California at Los Angeles (UCLA) Jonsson Cancer Center to obtain exclusive, worldwide diagnostic rights to its discovery of gene mutations believed to be associated with drug resistance to Gleevec® (imatinib mesylate), the current first-line therapy for patients with chronic myeloid leukemia (CML).

Yahoo News (http://biz.yahoo.com/prnews/051006/neth006.html?.v=27)